Verastem, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 87.37 million compared to USD 73.81 million a year ago. Basic loss per share from continuing operations was USD 3.96 compared to USD 4.57 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.42 USD | -0.04% | +13.13% | +38.70% |
Apr. 18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
Apr. 18 | Verastem Oncology Announces Executive Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.70% | 289M | |
+3.59% | 106B | |
+7.02% | 23.47B | |
-14.75% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-9.41% | 16.78B | |
+5.27% | 14.41B | |
+37.37% | 12.86B | |
+328.13% | 8.78B |
- Stock Market
- Equities
- VSTM Stock
- News Verastem, Inc.
- Verastem, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023